HeartSciences Inc. Adds Fortitude Interim Financials in 8‑K Amendment

What Happened

• HeartSciences Inc. filed an Amendment to its Form 8‑K on August 19, 2026 (Item 9.01) to provide Fortitude’s unaudited interim financial statements as of and for the six months ended June 30, 2026 and 2025.
• The amendment supplements the Initial Form 8‑K and Amendment No. 1 and is part of disclosure related to the proposed transaction between HeartSciences and Fortitude. HeartSciences previously filed a preliminary proxy statement on Schedule 14A on July 27, 2026.

Key Details

• Filing date of this amendment: August 19, 2026.
• Financial periods covered: six months ended June 30, 2026 and six months ended June 30, 2025 (unaudited interim statements for Fortitude).
• Proxy status: preliminary proxy filed July 27, 2026; a definitive proxy will be mailed to shareholders once filed.
• Participants in the solicitation may include directors and executive officers of HeartSciences and Fortitude and certain executive officers of Digital Currency Group, Inc. (Fortitude’s parent).

Why It Matters

• The added interim financials give HeartSciences’ shareholders and investors more recent financial information about Fortitude, which is material to evaluating the proposed merger/transaction.
• Investors should review the preliminary and, when available, the definitive proxy and related SEC filings (at www.sec.gov) before making voting or investment decisions; the filing emphasizes these materials contain important information and that the SEC/state regulators have not approved the transaction.